SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) lower blood glucose levels by inhibiting SGLT2 in the renal tubules and have been shown to reduce cardiovascular (CV) risk in subjects with T2DM [9].